title: [The clinical picture and treatment of depression spectrum disorders in patients with cardiovascular disease].
abstract: OBJECTIVE
  To study the impact of depressive and anxious disorders on the course of cardiovascular disease (CVD) and the specific features of clinical changes during combined pharmacotherapy (with cardiovascular agents and antidepressants).
  
  
  METHODS
  Seventy-eight patients with arterial hypertension (AH), acute myocardial infarction (AMI), chronic heart failures (CHF), or concomitant affective spectrum disorders were examined. Clinicopsychopathological and clinicofunctional studies were conducted.
  
  
  RESULTS
  Statistically significantly higher degrees of anxiety and depression were revealed in patients with AH and in those with CHF than in patients with prior AMI. After AMI, the degree of psychopathological symptomatology reduced during treatment more rapidly than that in patients with AH and in those with CHF. In all three groups, combined therapy using the antidepressant tianeptine (coaxil) improved intracardiac hemodynamics and left ventricular structural and geometric parameters.
  
  
  CONCLUSIONS
  Anxious and depressive disorders substantially affect the formation of a clinical picture in CVD. Inclusion of tianeptine (coaxil), that has antidepressive and anxiolytic activities, into the combined therapy of patients with CVD and depression spectrum disorders leads to a reduction in affective symptomatology, contributing to the positive impact on intracardiac hemodynamic and left ventricular structural and geometric parameters.
authors.forename: T V
authors.initials: TV
authors.lastname: Dovzhenko
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Vasiuk
authors.forename: M V
authors.initials: MV
authors.lastname: Semiglazova
authors.forename: V N
authors.initials: VN
authors.lastname: Krasnov
authors.forename: A V
authors.initials: AV
authors.lastname: Lebedev
authors.forename: K V
authors.initials: KV
authors.lastname: Tarasova
mesh_terms: D000328:Adult; D000341:Affective Disorders, Psychotic / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology*; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology*; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D013841:Thiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000929:Antidepressive Agents, Tricyclic; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D004232:Diuretics; D013841:Thiazepines; C050504:tianeptine